Fight Aging! Newsletter, March 14th 2022
This study tests the feasibility of chronically elevating skeletal muscle NAD+ in mice and investigates the putative effects on mitochondrial respiratory capacity, insulin sensitivity, and gene expression. The metabolic effects of NR and PT treatment were modest. We conclude that the chronic elevation of skeletal muscle NAD+ by the intravenous injection of NR is possible but does not affect muscle respiratory capacity or insulin sensitivity in either sedentary or physically active mice. Our data have implications for NAD+ precursor supplementation regimens.
Muscle Strengthening Activities in Later Life Correlate ...
Source: Fight Aging! - March 13, 2022 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Many Mediocre Cancer Therapies Become Much Better When More Targeted to Cancerous Tissues
One of the important areas of cancer research and development that appears to receive a great deal of attention and funding, but in practice seems slow to make it from the laboratory to the clinic, is the targeting of therapeutics to cancerous cells. Reductio ad absurdum, near any of dozens of existing chemotherapeutics would do the job of completely clearing tumors, with minimal to no side-effects, if one could only find a way to delivery tiny amounts of the therapeutic to every cancer cell while avoiding every healthy cell. The inability to target treatments this effectively is exactly why cancer remains such a problem. ...
Source: Fight Aging! - March 9, 2022 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Radiological findings :peritoneal carcinomatosis
Sharing a poster presentation done in Medcon2019 by Harika B 1styear PG& DR.ANV Prasad, Associate Professor NRI Institute of Medical Sciences CT Findings: Severe ascites seen. Multiple small enhancing nodules seen in the parietal peritoneum, visceral peritoneum and omentum with predominant pelvic distribution.Heterogeneously enhancing lesion of 3x2.1x1.8cm seen in RIF. Appendix is not seen separately from the lesion. Final Impression of Peritoneal carcinomatosis (pseudomyxoma peritoni) - likely due to mucinous adeno Ca. appendix.Peritoneal carcinomatosis(PC) is the term given to malignant tumour seeding...
Source: Sumer's Radiology Site - September 14, 2019 Category: Radiology Authors: Sumer Sethi Source Type: blogs
Healthcare.gov Improvements And New Investigative Reports (Updated)
This report is beyond the scope of this blog. (Source: Health Affairs Blog)
Source: Health Affairs Blog - October 23, 2015 Category: Health Management Authors: Timothy Jost Tags: Costs and Spending Following the ACA Medicaid and CHIP ACA Marketplace budget reconciliation insurance fraud open enrollment Prevention Preventive Services Mandate social security Source Type: blogs
Cases: "Am I really going to have to live like this?": The Role of Octreotide in Patients with Persistent Nausea and Vomiting after Venting Gastrostomy
Discussion:Malignant bowel obstruction can occur with any cancer but is most commonly associated with advanced ovarian cancer, where it occurs in up to 50% of patients. It generally indicates a poor prognosis and carries a heavy symptom burden predominated by nausea, vomiting and abdominal pain. Patients with carcinomatosis, like Ms BB, are generally not candidates for surgical correction of the obstruction or endoscopic stenting. Fortunately, medical management can be very effective. Abdominal pain is treated with opioids and nausea is treated with metoclopramide in partial obstructions and haloperidol in complete obstruc...
Source: Pallimed: A Hospice and Palliative Medicine Blog - April 10, 2014 Category: Palliative Carer Workers Authors: Christian Sinclair Source Type: blogs
NIH Public-Private Partnerships to Bring Therapies from Bench to Bedside
The objective of this project is to develop a treatment called recombinant human LCAT that would act as a replacement therapy to offset the deficiency caused by LCAT deficiency syndrome.
Spinal Cord Injury: Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury, George Maynard, Ph.D., vice president, Preclinical Development Axerion Therapeutics, Inc., New Haven, Conn. Recovery after a spinal cord injury is limited, as nerve cell growth is virtually nonexistent in the adult spinal cord. This project aims to develop a compound called Nogo Receptor Decoy to rewire nerve cells that promote the reco...
Source: Policy and Medicine - January 7, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
